PRLD Latest Press Releases

-- September 11, 2026 --

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference Globe Newswire 7:01 AM

-- September 10, 2026 --

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader Globe Newswire 7:01 AM

-- August 11, 2026 --

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 7:00 AM

-- May 12, 2026 --

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 7:01 AM

-- April 20, 2026 --

Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering Globe Newswire 6:30 AM

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 Globe Newswire 6:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software